Trial reportLipids in health and disease2016
Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A
Trial report in Lipids in health and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- Carbohydrate intake attenuates post-exercise plasma levels of cytochrome P450-generated oxylipins.PloS one · 2019Trial
- Continuous Glucose Monitoring Systems Can Meet the Challenge of Glucose Management and Beyond in Individuals with Type 2 Diabetes: An Expert Multidisciplinary Position.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers.Frontiers in endocrinology · 2025Review
- Article
- Insulin Pump Therapy for Patients With Type 2 Diabetes Mellitus: Evidence, Current Barriers, and New Technologies.Journal of diabetes science and technology · 2021Review
- Vascular Effects of Avocado Seed Glycosides during Diabetes-induced Endothelial Damage.Cardiovascular & hematological disorders drug targets · 2020Article
- Lipoprotein-associated phospholipase A2: The story continues.Medicinal research reviews · 2020Review
- Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?Current cardiology reviews · 2020Review
- Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes.Journal of inherited metabolic disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChina has the highest absolute disease burden of diabetes worldwide. For diabetic patients, diabetes-related vascular complications are major causes of morbidity and mortality. The roles of lipoprotein-associated phospholipase A
methodsIn total, 90 patients with newly diagnosed type 2 diabetes mellitus were enrolled. All patients received continuous subcutaneous insulin infusion (CSII) for approximately 2 weeks. Intravenous glucose-tolerance test (IVGTT) and oral glucose-tolerance test (OGTT) were performed, and plasma concentrations of Lp-PLA
resultsLevels of Lp-PLA
conclusionsLp-PLA
trial registrationChiCTR-TRC-10001618 2010 September 16.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.